# Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.

> **NCT00244127** · PHASE2 · UNKNOWN · sponsor: **Zeneus Pharma** · enrollment: 75 (—)

## Conditions studied

- Aggressive Non-Hodgkin's Lymphoma in the Elderly.

## Interventions

- **DRUG:** Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)

## Key facts

- **NCT ID:** NCT00244127
- **Lead sponsor:** Zeneus Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 75 (—)
- **Last updated:** 2005-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00244127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00244127, "Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00244127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*